

Payments to Healthcare Professionals

Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) or Patient Organizations (PO) benefit patients. These relationships have delivered numerous breakthrough medicines and have helped improve the way many diseases are treated and managed.

Our work together includes a range of activities, from clinical research to sharing best clinical practices. As part of these collaborations, Novartis may provide payments or other “transfers of value” to healthcare professionals and organizations to compensate them for their time, expertise, and services.

Bringing greater transparency to this already well-regulated relationship helps build understanding of these collaborations and address public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, healthcare professionals, government officials and the public. It also supports our broader commitment to transparency, data sharing, and high ethical business standards.

Novartis has long been dedicated to improving [clinical trial data transparency](#) and discloses [relationships with patient organizations](#).

In several countries, we publish information about payments and other transfer of values to Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with local laws, regulations, and industry codes.

About our reporting practices

Europe

Across Europe, Novartis annually discloses payments and other transfers of value in line with the [European Federation of Pharmaceutical Industries and Associations \(EFPIA\) Disclosure Code](#) and its local transpositions. [The EFPIA Disclosure Code 2026 Self-Certification Letter \(PDF 0.1 MB\)](#) signed by Patrick Horber, Novartis President, International, confirms the application of the [principles of the EFPIA Disclosure Code](#). The letter from previous year is available [here \(PDF 0.4 MB\)](#).

United States

Under the Sunshine Act, Novartis is required each year to submit data to the [Centers for Medicare and Medicaid Services \(CMS\) Open Payments Program](#) (commonly known as [the Sunshine Act](#)) as an applicable manufacturer.

CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial relationships and makes it available to the public annually through the [CMS Open Payments website](#).

[Read more about our Payments to Healthcare Professionals in the United States.](#)

Rest of the world

In addition to the EFPIA countries and the United States, we publicly disclose transfers of value in Australia, Brazil, Colombia, Canada, Israel, Japan and New Zealand.

In India, Indonesia, Philippines and Saudi Arabia, transfers of value are reported to the government.

In South Korea and Turkey, transfers of value are collected and shared with the Ministry of Health upon request.

All disclosure reports

Australia

Disclosure Report

[English](#)

Austria

Disclosure Report

[Novartis](#)

[Sandoz](#)

Belgium

Disclosure Report

Novartis

[French](#)

[Dutch](#)

Sandoz

[French](#)

[Dutch](#)

Bosnia and Herzegovina

Below is the disclosure information for Bosnia and Herzegovina in English as per EFPIA regulations. In case of questions please [contact us](#).

2025

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Brazil

Disclosure Report

[Portuguese](#)

Bulgaria

Disclosure Report

[Novartis](#)

[Sandoz](#)

Canada

Disclosure Report

Novartis

[English](#)

[French](#)

Sandoz

[English](#)

[French](#)

Colombia

Disclosure Report

[Spanish](#)

Croatia

Sukladno pravilima EFPIA udruženja niže su navedeni podaci na hrvatskom jeziku za objavu za Hrvatsku. U slučaju pitanja molimo Vas da nas [kontaktirate](#).

2025

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 1 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Cyprus

Below is the disclosure information for Cyprus in English as per EFPIA regulations. In case of questions please [contact us](#).

2025

Novartis

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Czech Republic

Disclosure Report

[Novartis](#)

[Sandoz](#)

Denmark

Disclosure Report

[Novartis](#)

[Sandoz](#)

Estonia

Disclosure Report

[Estonian](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Finland

Disclosure Report

[Novartis](#)

[Sandoz](#)

France

Disclosure Report

[French](#)

Germany

Disclosure Report

[Novartis](#)

[Sandoz](#)

Greece

Disclosure Report

[Greek](#)

Hungary

Disclosure Report

[Novartis](#)

[Sandoz](#)

Iceland

Disclosure Report

[Novartis](#)

[Sandoz](#)

Ireland

Disclosure Report

[English](#)

Israel

Disclosure Report

[Hebrew](#)

Italy

Disclosure Report

[Italian](#)

For 2023 Sandoz Disclosure reports, please refer to [-Codice sulla Trasparenza | Sandoz Italia](#)

Japan

Disclosure Report

[Novartis](#)

[Sandoz](#)

Latvia

Disclosure Report

[Latvian](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Lithuania

Disclosure Report

[Lithuanian](#)

Luxembourg

Below is the disclosure information for Luxembourg in English as per EFPIA regulations. In case of questions please [contact us](#).

2025

Novartis

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Malta

Below is the disclosure information for Malta in English as per EFPIA regulations. In case of questions please [contact us](#).

2025

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Netherlands

Disclosure Report

[Novartis](#)

[Sandoz](#)

New Zealand

Disclosure Report

[English](#)

North Macedonia

Below is the disclosure information for North Macedonia in English as per EFPIA regulations. In case of questions please [contact us](#).

2025

Novartis

[Disclosure Report \(PDF 0.9 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Norway

Disclosure Report

[Novartis](#)

[Sandoz](#)

Philippines

Disclosure Report

[English](#)

Poland

Disclosure Report

[Polish](#)

Portugal

Disclosure Report

[Portuguese](#)

Romania

Disclosure Report

[Novartis](#)

[Sandoz](#)

Russia

Disclosure Report

[Novartis](#)

[Sandoz](#)

Serbia

U prilogu se nalaze informacije koje će biti objavljene za Srbiju, na srpskom jeziku, po regulativi EFPIE. U slučaju bilo kakvih pitanja budite slobodni da nas [kontaktirate](#).

2025

Novartis

[Disclosure Report \(PDF 0.6 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.7 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

Slovakia

Disclosure Report

[Novartis](#)

[Sandoz](#)

Slovenia

Spodaj so glede na zahteve EFPIA v slovenskem jeziku objavljeni podatki o prenosih sredstev. V primeru morebitnih vprašanj nas prosimo [kontaktirajte](#).

2025

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

2024

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2023

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

South Korea

Disclosure Report

[Novartis](#)

Spain

Disclosure Report

[Novartis](#)

[Sandoz](#)

Sweden

Disclosure Report

[Novartis](#)

[Sandoz](#)

Switzerland

Disclosure Report

Novartis

[German](#)

[French](#)

Sandoz

[German](#)

[French](#)

Turkey

Disclosure Report

[Novartis](#)

[Sandoz](#)

UK

Disclosure Report

[Novartis](#)

[Sandoz](#)

Ukraine

Disclosure Report

[Ukrainian](#)

United States

Disclosure Report

[Novartis](#)

[Sandoz](#)

List of links present in page

1. <https://www.novartis.com/healthcare-professionals/payments-healthcare-professionals>
2. <https://www.novartis.com/clinicaltrials>
3. <https://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding>
4. <https://www.efpia.eu/relationships-code/the-efpia-code/>
5. https://www.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2026.pdf
6. <https://www.efpia.eu/relationships-code/healthcare-professionals-hcps/>
7. https://www.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2025.pdf
8. <https://www.cms.gov/>
9. <https://www.novartis.com/us-en/esg/ethics-risk-and-compliance/payments-hcps-hcos>
10. <https://openpaymentsdata.cms.gov/search>
11. <https://www.novartis.us/corporate-responsibility/payments-hcps-hcos>
12. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia/financial-transparency>
13. <https://www.novartis.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
14. <https://www.sandoz.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
15. <https://www.novartis.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
16. <https://www.novartis.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
17. <https://www.sandoz.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
18. <https://www.sandoz.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
19. <https://www.novartis.com/our-company/contact-us/office-locations>
20. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-and-herzegovina-2025.pdf
21. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-and-herzegovina-2025.pdf
22. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-and-herzegovina-2024.pdf
23. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-and-herzegovina-2024.pdf
24. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2023.pdf
25. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2023.pdf
26. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
27. <https://declarasus.saude.mg.gov.br/>
28. <https://www.novartis.com/bg-bg/esg/transparency>
29. <https://www.sandoz.bg/za-nas/korporativna-otgovornost/prozrachnost>
30. <https://www.novartis.ca/about-us/corporate-responsibility/transparency-voluntary-disclosure-payments-healthcare>
31. <https://www.novartis.ca/fr/about-us/corporate-responsibility/la-transparence-divulgate-volontaire-des-paiements-aux>
32. <https://www.sandoz.ca/transparency-initiative>
33. <https://www.sandoz.ca/fr/initiative-transparence>
34. <https://www.novartis.com/co-es/sobre-novartis/etica-e-integridad>
35. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4586](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4586)
36. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2025.pdf
37. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2025.pdf
38. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2024.pdf
39. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2024.pdf
40. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2023.pdf
41. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2023.pdf
42. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
43. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4501](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4501)
44. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2025.pdf
45. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2025.pdf
46. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2024.pdf
47. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2024.pdf
48. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2023.pdf
49. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2023.pdf
50. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
51. <https://www.novartis.cz/cs/transparentni-spoluprace-zverejneni>
52. <https://www.sandoz.cz/doing-business-responsibly>
53. <https://www.novartis.dk/om-novartis/hvem-samarbejder-vi-med#ui-id-1=0>
54. <https://www.sandoz.dk/transparency-disclosure-efpia>
55. <https://www.novartis.ee/koostoeoe-tervishoiutoeetajatega>
56. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
57. <https://www.novartis.fi/novartis-yrityksena/yritysvastuu/yhteistyö>
58. <https://www.sandoz.fi/transparency-disclosure-efpia>
59. <https://www.novartis.fr/propos-de-novartis/notre-activite/transparence-des-relations>
60. <https://www.novartis.de/transparenzkodex>
61. <https://www.sandoz.de/ueber-uns/verantwortungsbewusste-geschaeftsfuehrung/transparenz-von-leistungen-fachkreisangehoerige>
62. <https://www.novartis.gr/sustainable-development/business-ethic/disclosure-code>
63. <https://www.novartis.com/hu-hu/egeszsegugyi-szakemberek/atlatthatosag>

64. <https://www.sandoz.hu/rolunk/felelos-uzletvitel>
65. <https://frumtok.is/sidareglur/>
66. <https://www.sandoz.dk/transparency-disclosure-efpia>
67. <https://www.novartis.ie/ethics-and-compliance-transparency>
68. https://www.health.gov.il/Subjects/Finance/Pages/donation_reports.aspx
69. <https://www.novartis.it/su-di-noi/responsabilita-sociale/etica-persone-ambiente/codice-sulla-trasparenza>
70. <https://www.sandoz.it/su-di-noi/condotta-responsabile-del-business/codice-sulla-trasparenza/>
71. <https://www.novartis.com/jp-ja/esg/transparency>
72. <https://www.sandoz.jp/about-us>
73. <https://www.novartis.com/lv-lv/veselibas-aprupes-specialisti/sadarbiba-ar-veselibas-aprupes-specialistiem>
74. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
75. <https://www.novartis.com/lt-lt/sveikatos-prieziuros-specialistai/bendradarbiavimas-su-sveikatos-prieziuros-specialistais>
76. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4681](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4681)
77. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2025.pdf
78. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2025.pdf
79. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2024.pdf
80. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2024.pdf
81. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2023.pdf
82. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2023.pdf
83. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
84. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4706](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4706)
85. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2025.pdf
86. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2025.pdf
87. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2024.pdf
88. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2024.pdf
89. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2023.pdf
90. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2023.pdf
91. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
92. <https://www.novartis.nl/transparantie-nederland>
93. <https://www.sandoz.nl/over-ons/verantwoord-zakendoen>
94. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia-new-zealand/financial-transparency-for-new-zealand>
95. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4701](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4701)
96. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2025.pdf
97. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2025.pdf
98. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2024.pdf
99. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2024.pdf
100. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2023.pdf
101. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2023.pdf
102. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
103. <https://www.novartis.com/no-no/om-oss/pengeoverforing-til-helsetjenesten>
104. <https://www.sandoz.no/transparency-disclosure-efpia>
105. <https://www.novartis.com/ph-en/esg/financial-transparency-philippines>
106. <https://www.novartis.pl/wspolpraca-z-przedstawicielami-zawodow-medycznych-oraz-organizacjami-ochrony-zdrowia#ui-id-1=0>
107. <https://www.novartis.pt/transferencias-de-valor-profissionais-e-organizacoes-de-saude>
108. <https://www.novartis.com.ro/contributia-noastra/transparenta>
109. <https://www.sandoz.ro/despre-noi/etica-si-conformitate>
110. <https://www.novartis.ru/about-us/corporate-responsibility/general-disclosure>
111. <https://www.sandoz.ru/o-kompanii/otvetstvennoe-vedenie-biznesa/general-disclosure>
112. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4801](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4801)
113. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2025.pdf
114. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2025.pdf
115. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2024.pdf
116. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2024.pdf
117. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2023.pdf
118. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2023.pdf
119. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2023.pdf
120. https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2023.pdf
121. <https://www.novartis.sk/o-nas/spolocenska-zodpovednost/transparentnost-v-platbach-zdravotnickym-pracovnikom>
122. <https://www.sandoz.sk/o-nas/transparentna-spolupraca>
123. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4826](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4826)
124. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2025.pdf

125. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2025.pdf
126. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2024.pdf
127. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2024.pdf
128. https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2023.pdf
129. https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2023.pdf
130. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
131. <https://www.novartis.com/kr-ko/esg/corporate-responsibility/doing-business-responsibility>
132. <https://www.novartis.es/sobre-novartis/responsabilidad-social/practica-empresarial-responsable/transparencia-en-las>
133. <https://www.sandozfarma.es/sobre-sandoz/responsabilidad-social-corporativa/practica-empresarial-responsable/transferencias-de>
134. <https://www.novartis.se/om-novartis/vart-ansvar/transparent-samarbete>
135. <https://www.sandoz.se/transparency-disclosure-efpia>
136. <https://www.novartis.com/ch-de/gesellschaft-und-umwelt/offenlegung-der-geldwerten-leistungen>
137. <https://www.novartis.com/ch-fr/societe-environnement/publication-des-transferts-de-valeurs>
138. <https://www.sandoz-pharmaceuticals.ch/de/ueber-uns/verantwortungsvolle-geschaefsfuehrung/offenlegung-der-geldwerten-leistungen-fachpersonen>
139. <https://www.sandoz-pharmaceuticals.ch/fr/ueber-uns/verantwortungsvolle-geschaefsfuehrung/publication-des-transferts-des-valeurs-aux>
140. <https://www.novartis.com.tr/hakkimizda/kurumsal-sorumluluk>
141. <https://www.sandoz.com.tr/hakkimizda/yapma-sorumlulugumuz>
142. <https://www.novartis.com/uk-en/esg/transparency/healthcare-professional-payment-transparency>
143. <https://www.sandoz.uk.com/about-us/transparency/>
144. <https://aprad.org.ua/tematichni-rozdili/rozkrittia-informatsiyi/>
145. <https://www.pharma.us.novartis.com/corporate-responsibility/physician-payments-sunshine-act>
146. <https://www.us.sandoz.com/about-us/doing-business-responsibly>